
Sign up to save your podcasts
Or


This week’s episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam.
By Sam and Karine4.8
189189 ratings
This week’s episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam.

324 Listeners

498 Listeners

120 Listeners

58 Listeners

297 Listeners

3,357 Listeners

1,144 Listeners

187 Listeners

43 Listeners

191 Listeners

515 Listeners

369 Listeners

248 Listeners

59 Listeners

42 Listeners